companiesCompany

ExCellThera

ExCellThera is a Montreal cell-therapy company that uses the small molecule UM171 to multiply blood stem cells from cord blood, making transplants possible for patients who would otherwise lack a donor.

Also called: ExCellThera Inc.

ExCellThera was spun out of Université de Montréal around UM171, a molecule discovered in Guy Sauvageau's laboratory that expands haematopoietic stem cells in culture. Its product, dorocubicel (ECT-001, UM171-expanded cord blood), lets a small cord blood unit be grown into a graft for adults with high-risk blood cancers who lack a matched donor. Phase 2 trials in acute leukaemia and myelodysplastic syndromes have reported low rates of chronic graft-versus-host disease and relapse.

Headquarters

Montreal, CA

Scorecard

All companies

#387of 1244 companies, score 9

approved products +6
modalities +2
regions +1

1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.

Type

Cell therapy

Website

www.excellthera.com/

Founded

2015

Products

1top

ApprovedAllogeneic expanded cord blood cell therapy (ATMP)

Dorocubicel (UM171-expanded cord blood) · Zemcelpro

Zemcelpro is a laboratory-expanded umbilical cord blood transplant for adults with blood cancers who need a donor stem cell transplant but have no suitable matched donor; expanding the cells lets a single small cord blood unit be enough.